JAGX · Jaguar Health, Inc.

Jaguar Health received a Nasdaq Staff notice on May 1, 2026, indicating non-compliance with the minimum 500,000 publicly held shares requirement due to a 1-for-35 reverse stock split effective April 30, 2026. The company had approximately 401,226 publicly held shares post-split. Additionally, the Staff noted that the company would remain non-compliant with both the bid price and publicly held shares requirements until the latter is cured, after which it must evidence a $1.00 closing bid price for 10 consecutive business days. On May 4, 2026, certain third-party investors exercised pre-funded warrants, increasing the company's issued and outstanding shares to 513,974 and publicly held shares to 513,939, thereby curing the publicly held shares deficiency. The company is awaiting formal confirmation from Nasdaq. This event is material as it directly impacts the company's continued listing on Nasdaq.